[Combined immunomodulating therapy in rheumatoid arthritis].
Monotherapy with methotrexate (MT) was compared to combined therapy MT+tactivin (T) in a 2-year clinical trial including 127 patients with rheumatoid arthritis (RA). MT was given to 88 patients in a weekly dose 7.5 mg. In 39 patients this dose was given in combination with subcutaneous injections of T (100 micrograms two times a week for a months, then once a week). Both treatments induced a significant decline in severity of arthralgia, in the number of joints with inflammation, in the level of C-reactive protein and in ESR. Morning stiffness and pains in the joints at palpation were achieved after MT+T combination. Side effects were similar in both treatments.
Oliunin
Iu A
IuA
Balabanova
R M
RM
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use; D013949:Thymus Extracts / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D010455:Peptides; D013949:Thymus Extracts; C036191:T-activin; D008727:Methotrexate
Kombinirovannaia immunomoduliruiushchaia terapiia revmatoidnogo artrita.